PXD059004-1

PXD059004 is an original dataset announced via ProteomeXchange.

Title	Phase I study of immunopeptidome-guided personalized multi-peptide vaccines in chronic lymphocytic leukemia patients under BTK-inhibitor-based regimes
Description	Cancer peptide vaccines hold promise as therapeutic approach, but their effectiveness has been hampered by lack of suitable antigens and the variability of HLA backgrounds among patients, which restricts their applicability.. We here introduce a novel warehouse concept for the construction of personalized peptide vaccines and outline its successful implementation in a Phase II clinical trial in patients with chronic lymphocytic leukemia (CLL) after first-line therapy. 20 CLL patients, in at least partial remission (PR) after treatment with Bruton’s tyrosine kinase inhibitors, were vaccinated with a personalized vaccine selected from a premanufactured immunopeptidome-defined CLL-associated peptide warehouse. Primary objective was immunogenicity, secondary objectives were safety and minimal residual disease (MRD) response. Immunopeptidome-guided vaccine composition was feasible throughout, confirming the success of warehouse-based vaccine design. Vaccination was well tolerated, with local injection site reactions the most common adverse events. Almost all patients showed vaccine-induced T cell responses, attributable to their inability to mount strong immune responses after immune-chemotherapy and the lack of potent adjuvant formulations. Both issues are addressed within a follow-up trial (NCT04688385), combining the here proven immunopeptidome-guided warehouse-based vaccine design with a strong novel adjuvant to evaluate personalized multi- peptide vaccination in CLL patients under T cell supportive BTK inhibitor therapies.
HostingRepository	PRIDE
AnnounceDate	2026-01-22
AnnouncementXML	Submission_2026-01-22_14:23:12.631.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Marcel Wacker
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: NEWT:9606;
ModificationList	monohydroxylated residue
Instrument	timsTOF Pro; Orbitrap Fusion Lumos

Revision	Datetime	Status	ChangeLog Entry
0	2024-12-18 09:54:45	ID requested
⏵ 1	2026-01-22 14:23:13	announced

10.1016/s2352-3026(25)00323-0;

Heitmann JS, Maringer Y, Jung S, Wacker M, Hackenbruch C, Polster M, Marconato M, Nelde A, Bauer J, Zwick M, Baur AS, Metzger A, Krolla C, Andrieux G, K, ö, hler N, Boerries M, Denk M, Zieschang L, Kammer C, Hoenisch-Gravel N, Richter M, Oezbek MT, Wirths S, Dengler A, Dubbelaar ML, Pumptow M, Martus P, Br, ü, ggemann M, Rammensee HG, Salih HR, Walz JS, Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study. Lancet Haematol, 13(2):e74-e85(2026) [pubmed]

submitter keyword: Human, CLL, Immunopeptidomics, LC-MS/MS

Juliane Sarah Walz
contact affiliation	Department of Peptide-based Immunotherapy, Institute of Immunology, University and University Hospital Tübingen, Tübingen, Germany
contact email	Juliane.Walz@med.uni-tuebingen.de
lab head
Marcel Wacker
contact affiliation	Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany
contact email	marcel.wacker@uni-tuebingen.de
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/01/PXD059004

PRIDE project URI

• PRIDE
  1. PXD059004
     1. Label: PRIDE project
     2. Name: Phase I study of immunopeptidome-guided personalized multi-peptide vaccines in chronic lymphocytic leukemia patients under BTK-inhibitor-based regimes